BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 7551840)

  • 1. Long-term results with M-VAC for advanced urothelial cancer: high relapse rate and low survival in patients with a complete response.
    Igawa M; Urakami S; Shiina H; Ishibe T; Kadena H; Usui T
    Br J Urol; 1995 Sep; 76(3):321-4. PubMed ID: 7551840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of dose intensity on M-VAC therapy for advanced urothelial cancer.
    Miyanaga N; Akaza H; Shimazui T; Ohtani M; Koiso K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S5-8. PubMed ID: 7527735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
    Kobayashi H; Obata K
    Cancer Chemother Pharmacol; 1994; 35 Suppl():S14-7. PubMed ID: 7994781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced renal pelvic and ureteral carcinoma].
    Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Kume T; Masu C; Ishino T; Nakatsu H
    Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2577-82. PubMed ID: 2673046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
    Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Ahmed T; Weiselberg LR; Geller N; Hollander PS; Herr HW; Sogani PC
    J Urol; 1985 Mar; 133(3):403-7. PubMed ID: 4038749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse.
    Sternberg CN; Yagoda A; Scher HI; Watson RC; Geller N; Herr HW; Morse MJ; Sogani PC; Vaughan ED; Bander N
    Cancer; 1989 Dec; 64(12):2448-58. PubMed ID: 2819654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [M-VAC chemotherapy for advanced urothelial cancer--side effects and their management].
    Noguchi S; Kubota Y; Shuin T; Masuda M; Misaki H; Yao M; Kondoh K; Sakuramoto T; Hosaka M
    Hinyokika Kiyo; 1994 Aug; 40(8):677-82. PubMed ID: 7942364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of modified M-VAC chemotherapy for advanced urothelial carcinoma].
    Miura N; Numata K; Azuma K; Hashine K; Sumiyoshi Y
    Nihon Hinyokika Gakkai Zasshi; 2007 May; 98(4):589-94. PubMed ID: 17564101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Early clinical result of modified M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for advanced transitional cell carcinoma of renal pelvis and ureter].
    Shishido S; Hayakawa M; Higa I; Koyama Y; Hatano T; Osawa A
    Hinyokika Kiyo; 1990 Apr; 36(4):401-5. PubMed ID: 2378303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: the Princess Margaret Hospital experience.
    Tannock I; Gospodarowicz M; Connolly J; Jewett M
    J Urol; 1989 Aug; 142(2 Pt 1):289-92. PubMed ID: 2746745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up in patients treated with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) for transitional cell carcinoma of urinary bladder: cause for concern.
    Connor JP; Olsson CA; Benson MC; Rapoport F; Sawczuk IS
    Urology; 1989 Dec; 34(6):353-6. PubMed ID: 2595880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Two cases of urothelial cancer responsive to high-dose-intensity methotrexate vinblastine doxorubicin and cisplatin (M-VAC) therapy].
    Fukuda H; Mitsumori K; Minagawa S; Kumazawa T; Tadachi K; Iinuma M; Satoh S; Satoh K; Habuchi T; Kato T
    Hinyokika Kiyo; 2005 Feb; 51(2):113-6. PubMed ID: 15773365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Outcome of treatment with surgical resection of the remaining tumor after modified M-VAC treatment for advanced urothelial carcinoma].
    Narita S; Nakano M; Matsuzaki M; Watanabe J; Morikawa H; Murata H; Oda H; Komatsu H
    Hinyokika Kiyo; 2005 Mar; 51(3):155-8. PubMed ID: 15852667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A clinical study on renal pelvic and ureteral cancer--with special reference to prognostic factors and adjuvant chemotherapy].
    Miyagawa Y; Oka T; Seko M; Tei N; Satoh E; Takano Y; Tsujimura A; Takaha M; Takeda M
    Nihon Hinyokika Gakkai Zasshi; 1998 Sep; 89(9):766-73. PubMed ID: 9796256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and cisplatin chemotherapy for metastatic urothelial carcinoma after failure of two courses of platinum-based regimens.
    Joung JY; Kwon WA; Cho IC; Kim EK; Park S; Yoon H; Seo HK; Chung J; Park WS; Lee KH
    Int J Urol; 2011 May; 18(5):350-7. PubMed ID: 21355894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Long-term results of M-VAC for the treatment of advanced urothelial cancer].
    Tachibana M; Iigaya T; Shibayama T; Baba S; Deguchi N; Jitsukawa S; Hata M; Tazaki H
    Nihon Hinyokika Gakkai Zasshi; 1989 Nov; 80(11):1644-50. PubMed ID: 2593440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II randomized trial of gallium nitrate plus fluorouracil versus methotrexate, vinblastine, doxorubicin, and cisplatin in patients with advanced transitional-cell carcinoma.
    McCaffrey JA; Hilton S; Mazumdar M; Sadan S; Heineman M; Hirsch J; Kelly WK; Scher HI; Bajorin DF
    J Clin Oncol; 1997 Jun; 15(6):2449-55. PubMed ID: 9196161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study.
    Loehrer PJ; Einhorn LH; Elson PJ; Crawford ED; Kuebler P; Tannock I; Raghavan D; Stuart-Harris R; Sarosdy MF; Lowe BA
    J Clin Oncol; 1992 Jul; 10(7):1066-73. PubMed ID: 1607913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.